Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets.
Coralea Kappel, Di Maria Jiang, Bryan Wong...
https://pubmed.ncbi.nlm.nih.gov/35337750Actively Recruiting
Age: 18Years +
All Genders
ID02906943
Ontario-wide Cancer Targeted Nucleic Acid Evaluation to Study Advanced Solid Tumors Using Next Generation Sequencing
Led by University Health Network, Toronto · Updated on 2026-06-05
10000
Participants Needed
7
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University Health Network, Toronto
Lead Sponsor
P
Princess Margaret Hospital, Canada
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating the use of targeted gene sequencing to better understand advanced, incurable solid tumors in patients receiving standard palliative treatments. The study aims to collect biomarker data from previously collected tumor samples to help guide future treatment decisions and identify suitable clinical trials. This research also seeks to develop a province-wide registry of gene sequencing results and a biobank of tumor and blood samples to support cancer research in Ontario. Participants will provide archival formalin-fixed paraffin embedded (FFPE) tumor tissue for targeted next generation sequencing (NGS) panel testing. Additional tumor tissue and blood samples will be collected for future research and stored in a centralized biorepository. The results of selected gene tests will be shared securely with the treating oncologist through a web portal. Remaining tumor DNA and blood samples may undergo further analysis to support test development and research. During the study, participants' health records will be reviewed and linked to health databases to gather information about their medical treatments and outcomes. Researchers will monitor how gene sequencing data is used in clinical care and research, including the number of patients included in the registry and biobank. The study will last for several years, with ongoing collection and analysis of data to improve understanding of cancer and its treatment.
CONDITIONS
Brief Title
Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Patients with histological confirmation of advanced solid tumor malignancies who are candidates for systemic therapy.
- Patients must have sufficient archived formalin-fixed paraffin embedded (FFPE) tumor tissue for molecular profiling.
- Patients must be 18 years old or older.
- Patients must have an ECOG performance status of 0 or 1.
- Patients must have a life expectancy of more than 6 months.
- Patients must have adequate organ functions.
- Patients must have signed and dated an informed consent form.
You will not qualify if you...
- Patients who have received more than 2 lines of prior cytotoxic therapy for their recurrent or metastatic disease, except Phase I trial candidates who may have had more than 2 prior treatments.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Surveillance
Duration - Up to 5 years
Participants with advanced solid tumors who are receiving standard palliative treatments are observed while archival tumor tissue and blood samples are collected for targeted next generation sequencing and future research.
Single visit for sample collection; follow-up assessments occur through medical record review and data collection
Trial Site Locations
Total: 7 locations
1
Juravinski Cancer Centre
Hamilton, Ontario, Canada
Active, Not Recruiting
2
Kingston General Hospital
Kingston, Ontario, Canada
Active, Not Recruiting
3
London Health Sciences Centre
London, Ontario, Canada
Active, Not Recruiting
4
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Actively Recruiting
5
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
6
Mount Sinai Hospital
Toronto, Ontario, Canada
Active, Not Recruiting
7
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Active, Not Recruiting
Loading map...
Research Team
S
Samanta Del Rossi
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
Lucy X Ma, Osvaldo Espin-Garcia, Philippe L Bedard...
https://pubmed.ncbi.nlm.nih.gov/35262412